A Discrepancy: Calcium Channel Blockers Are Effective for the Treatment of Hypertensive Left Ventricular Hypertrophy but Not as Effective for Prevention of Heart Failure

Arterial hypertension (HTN) is important due to its high prevalence, morbidity, and mortality rates. Calcium channel blockers (CCBs) are the first-line antihypertensive drugs. HTN can lead to heart failure (HF) by causing hypertensive left ventricular hypertrophy (HTN LVH). CCBs are recommended for...

Full description

Saved in:

Bibliographic Details
Published in	Medical principles and practice Vol. 31; no. 5; pp. 454 - 462
Main Authors	Koracevic, Goran, Perisic, Zoran, Stanojkovic, Maja, Stojanovic, Milovan, Zdravkovic, Milos, Tomasevic, Miloje, Djordjevic, Dragan, Mladenovic, Katarina, Koracevic, Maja, Trkulja, Jelena
Format	Journal Article
Language	English
Published	Basel, Switzerland S. Karger AG 01.12.2022
Subjects	Antihypertensive Agents - therapeutic use Antihypertensives Blood pressure Calcium Channel Blockers - therapeutic use Cardiovascular disease Diuretics Drugs Ejection fraction Heart attacks Heart failure Heart Failure - complications Heart Failure - drug therapy Heart Failure - prevention & control Humans Hypertension Hypertension - complications Hypertension - drug therapy Hypertension - epidemiology Hypertrophy, Left Ventricular - drug therapy Hypertrophy, Left Ventricular - prevention & control Mortality Original Paper Prevention Risk factors Heart failure Arterial hypertension Renin-angiotensin-aldosterone system Calcium channel blockers Left ventricular hypertrophy
Online Access	Get full text

Cover

Loading…

Abstract	Arterial hypertension (HTN) is important due to its high prevalence, morbidity, and mortality rates. Calcium channel blockers (CCBs) are the first-line antihypertensive drugs. HTN can lead to heart failure (HF) by causing hypertensive left ventricular hypertrophy (HTN LVH). CCBs are recommended for the treatment of HTN LVH. The aim of this study was to analyze the status of CCBs regarding (1) HTN LVH treatment and (2) capability to prevent HTN-induced HF in the guidelines. For this narrative review, the following databases were searched: Medline, Scopus, Science Direct, Springer, SAGE, Wiley, Oxford Journals, Cambridge, and Google Scholar. CCBs are effective antihypertensive drugs and a very good therapeutic option for HTN LVH as they can cause reverse LVH remodeling. Consequently, we may expect that CCBs would prevent HF. However, evidence suggests that CCBs confer less protection from HF than other first-line antihypertensive drugs. A negative inotropic action of nondihydropyridine CCBs may contribute to suboptimal protection against HF. This discrepancy is clinically relevant because CCBs are in one of the two recommended (single pill) combinations for the initial treatment of HTN. LVH is a strong risk factor for HF in HTN patients. When LVH arises, the risk of HF increases dramatically. CCBs are inferior to renin-angiotensin-aldosterone system blockers but still very effective in bringing about regression of HTN LVH; consequently, CCBs are expected to protect from HF. On the contrary, CCBs protect from HF less effectively than other first-line antihypertensive drugs. This discrepancy needs to be investigated further to improve clinical practice.
AbstractList	Arterial hypertension (HTN) is important due to its high prevalence, morbidity, and mortality rates. Calcium channel blockers (CCBs) are the first-line antihypertensive drugs. HTN can lead to heart failure (HF) by causing hypertensive left ventricular hypertrophy (HTN LVH). CCBs are recommended for the treatment of HTN LVH. The aim of this study was to analyze the status of CCBs regarding (1) HTN LVH treatment and (2) capability to prevent HTN-induced HF in the guidelines. For this narrative review, the following databases were searched: Medline, Scopus, Science Direct, Springer, SAGE, Wiley, Oxford Journals, Cambridge, and Google Scholar. CCBs are effective antihypertensive drugs and a very good therapeutic option for HTN LVH as they can cause reverse LVH remodeling. Consequently, we may expect that CCBs would prevent HF. However, evidence suggests that CCBs confer less protection from HF than other first-line antihypertensive drugs. A negative inotropic action of nondihydropyridine CCBs may contribute to suboptimal protection against HF. This discrepancy is clinically relevant because CCBs are in one of the two recommended (single pill) combinations for the initial treatment of HTN. LVH is a strong risk factor for HF in HTN patients. When LVH arises, the risk of HF increases dramatically. CCBs are inferior to renin-angiotensin-aldosterone system blockers but still very effective in bringing about regression of HTN LVH; consequently, CCBs are expected to protect from HF. On the contrary, CCBs protect from HF less effectively than other first-line antihypertensive drugs. This discrepancy needs to be investigated further to improve clinical practice. Arterial hypertension (HTN) is important due to its high prevalence, morbidity, and mortality rates. Calcium channel blockers (CCBs) are the first-line antihypertensive drugs. HTN can lead to heart failure (HF) by causing hypertensive left ventricular hypertrophy (HTN LVH). CCBs are recommended for the treatment of HTN LVH. The aim of this study was to analyze the status of CCBs regarding (1) HTN LVH treatment and (2) capability to prevent HTN-induced HF in the guidelines. For this narrative review, the following databases were searched: Medline, Scopus, Science Direct, Springer, SAGE, Wiley, Oxford Journals, Cambridge, and Google Scholar. CCBs are effective antihypertensive drugs and a very good therapeutic option for HTN LVH as they can cause reverse LVH remodeling. Consequently, we may expect that CCBs would prevent HF. However, evidence suggests that CCBs confer less protection from HF than other first-line antihypertensive drugs. A negative inotropic action of nondihydropyridine CCBs may contribute to suboptimal protection against HF. This discrepancy is clinically relevant because CCBs are in one of the two recommended (single pill) combinations for the initial treatment of HTN. LVH is a strong risk factor for HF in HTN patients. When LVH arises, the risk of HF increases dramatically. CCBs are inferior to renin-angiotensin-aldosterone system blockers but still very effective in bringing about regression of HTN LVH; consequently, CCBs are expected to protect from HF. On the contrary, CCBs protect from HF less effectively than other first-line antihypertensive drugs. This discrepancy needs to be investigated further to improve clinical practice.Arterial hypertension (HTN) is important due to its high prevalence, morbidity, and mortality rates. Calcium channel blockers (CCBs) are the first-line antihypertensive drugs. HTN can lead to heart failure (HF) by causing hypertensive left ventricular hypertrophy (HTN LVH). CCBs are recommended for the treatment of HTN LVH. The aim of this study was to analyze the status of CCBs regarding (1) HTN LVH treatment and (2) capability to prevent HTN-induced HF in the guidelines. For this narrative review, the following databases were searched: Medline, Scopus, Science Direct, Springer, SAGE, Wiley, Oxford Journals, Cambridge, and Google Scholar. CCBs are effective antihypertensive drugs and a very good therapeutic option for HTN LVH as they can cause reverse LVH remodeling. Consequently, we may expect that CCBs would prevent HF. However, evidence suggests that CCBs confer less protection from HF than other first-line antihypertensive drugs. A negative inotropic action of nondihydropyridine CCBs may contribute to suboptimal protection against HF. This discrepancy is clinically relevant because CCBs are in one of the two recommended (single pill) combinations for the initial treatment of HTN. LVH is a strong risk factor for HF in HTN patients. When LVH arises, the risk of HF increases dramatically. CCBs are inferior to renin-angiotensin-aldosterone system blockers but still very effective in bringing about regression of HTN LVH; consequently, CCBs are expected to protect from HF. On the contrary, CCBs protect from HF less effectively than other first-line antihypertensive drugs. This discrepancy needs to be investigated further to improve clinical practice. Arterial hypertension (HTN) is important due to its high prevalence, morbidity, and mortality rates. Calcium channel blockers (CCBs) are the first-line antihypertensive drugs. HTN can lead to heart failure (HF) by causing hypertensive left ventricular hypertrophy (HTN LVH). CCBs are recommended for the treatment of HTN LVH. The aim of this study was to analyze the status of CCBs regarding (1) HTN LVH treatment and (2) capability to prevent HTN-induced HF in the guidelines. For this narrative review, the following databases were searched: Medline, Scopus, Science Direct, Springer, SAGE, Wiley, Oxford Journals, Cambridge, and Google Scholar. CCBs are effective antihypertensive drugs and a very good therapeutic option for HTN LVH as they can cause reverse LVH remodeling. Consequently, we may expect that CCBs would prevent HF. However, evidence suggests that CCBs confer less protection from HF than other first-line antihypertensive drugs. A negative inotropic action of nondihydropyridine CCBs may contribute to suboptimal protection against HF. This discrepancy is clinically relevant because CCBs are in one of the two recommended (single pill) combinations for the initial treatment of HTN. LVH is a strong risk factor for HF in HTN patients. When LVH arises, the risk of HF increases dramatically . CCBs are inferior to renin-angiotensin-aldosterone system blockers but still very effective in bringing about regression of HTN LVH; consequently, CCBs are expected to protect from HF. On the contrary, CCBs protect from HF less effectively than other first-line antihypertensive drugs. This discrepancy needs to be investigated further to improve clinical practice.
Author	Stojanovic, Milovan Tomasevic, Miloje Djordjevic, Dragan Stanojkovic, Maja Koracevic, Goran Perisic, Zoran Zdravkovic, Milos Trkulja, Jelena Koracevic, Maja Mladenovic, Katarina
AuthorAffiliation	f Faculty of Science, Department of Biology and Ecology, University of Kragujevac, Kragujevac, Serbia g Medical Centre “Dom Zdravlja Nis”, Nis, Serbia a Faculty of Medicine, University of Nis, Nis, Serbia d Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia b Department for Cardiovascular Diseases, University Clinical Center Nis, Nis, Serbia e Clinic for Cardiology, Clinical Center of Serbia, Belgrade, Serbia c Institute for Treatment and Rehabilitation Niska Banja, Nis, Serbia
AuthorAffiliation_xml	– name: g Medical Centre “Dom Zdravlja Nis”, Nis, Serbia – name: b Department for Cardiovascular Diseases, University Clinical Center Nis, Nis, Serbia – name: a Faculty of Medicine, University of Nis, Nis, Serbia – name: d Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia – name: f Faculty of Science, Department of Biology and Ecology, University of Kragujevac, Kragujevac, Serbia – name: c Institute for Treatment and Rehabilitation Niska Banja, Nis, Serbia – name: e Clinic for Cardiology, Clinical Center of Serbia, Belgrade, Serbia
Author_xml	– sequence: 1 givenname: Goran surname: Koracevic fullname: Koracevic, Goran – sequence: 2 givenname: Zoran surname: Perisic fullname: Perisic, Zoran – sequence: 3 givenname: Maja surname: Stanojkovic fullname: Stanojkovic, Maja – sequence: 4 givenname: Milovan surname: Stojanovic fullname: Stojanovic, Milovan email: *Milovan Stojanovic, milovanstojanovic1987@gmail.com – sequence: 5 givenname: Milos surname: Zdravkovic fullname: Zdravkovic, Milos – sequence: 6 givenname: Miloje surname: Tomasevic fullname: Tomasevic, Miloje – sequence: 7 givenname: Dragan orcidid: 0000-0003-4966-0168 surname: Djordjevic fullname: Djordjevic, Dragan – sequence: 8 givenname: Katarina surname: Mladenovic fullname: Mladenovic, Katarina – sequence: 9 givenname: Maja orcidid: 0000-0001-6044-3557 surname: Koracevic fullname: Koracevic, Maja – sequence: 10 givenname: Jelena surname: Trkulja fullname: Trkulja, Jelena
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36044874$$D View this record in MEDLINE/PubMed
BookMark	eNptkk9vEzEQxVeoiP6BA3eELHGBw1J7d722e0AKoaVIAXIoXC3v7rhxu7EX2xspH4lviUPSCKKebPn95unNeE6zI-ssZNlLgt8TQsU5xpgWNRPFk-yEVEWZY0LJUbpjQnJGGTnOTkO4SxgvS_wsOy5rXFWcVSfZ7wn6ZELrYVC2XV-gqepbMy7RdKGshR597F17Dz6giQd0qTW00awAaedRXAC68aDiEmxETqPr9QA-gg0bYgY6op9J8aYde-V3qnfDYo2aMaJvLiIVDjznHlapxjj71xCUj-hKmX708Dx7qlUf4MXuPMt-XF3eTK_z2ffPX6aTWd5SImKuC0Vr1RGosYCKsk7ziirCG0bLruEtF7rhSlFe1TWtK8U6Rqv0QBpR8kJU5Vn2Yes7jM0SunbTgurl4M1S-bV0ysj_FWsW8tatpOCYlDVPBm93Bt79GiFEuUwThr5XFtwYZMGwwIRRUST0zQF650ZvU3uyEBiXpGaFSNTrfxPtozz8YgLOt0DrXQgetGxNVJsppoCmlwTLzZ7I_Z6kincHFQ-mj7G7kPfK34Lfk1_n8y0hh04n6tWj1M7kD8d104Y
CitedBy_id	crossref_primary_10_3390_jcm12175723 crossref_primary_10_1016_j_phymed_2023_154867 crossref_primary_10_36011_cpp_2023_5_e16 crossref_primary_10_1002_clc_24058 crossref_primary_10_2174_0115701611264647231110101700 crossref_primary_10_3389_fphar_2023_1322148
Cites_doi	https://doi.org/10.1016/S0140-6736(15)01225-8 https://doi.org/10.1177/1099800413494760 https://doi.org/10.1016/j.amjcard.2014.07.015 https://doi.org/10.1016/j.cjca.2020.02.086 https://doi.org/10.1161/HYPERTENSIONAHA.109.136655 https://doi.org/10.1038/ajh.2010.80 https://doi.org/10.5935/abc.20160164 https://doi.org/10.1093/ndt/13.3.564 https://doi.org/10.1253/circj.cj-66-0098 https://doi.org/10.1001/jama.2013.284427 https://doi.org/10.1097/HJH.0000000000000614 https://doi.org/10.1093/eurheartj/ehx525 https://doi.org/10.1161/CIRCHEARTFAILURE.112.972828 https://doi.org/10.1177/1074248418771341 https://doi.org/10.1016/j.annemergmed.2013.05.012 https://doi.org/10.1111/jch.13386 https://doi.org/10.1097/HJH.0b013e32832aa6d2 https://doi.org/10.1136/heart.89.6.589 https://doi.org/10.1038/s41440-019-0284-9 https://doi.org/10.1093/eurheartj/eht151 https://doi.org/10.2174/1570161115666170414120532 https://doi.org/10.11909/j.issn.1671-5411.2019.03.014 https://doi.org/10.4061/2011/495349 https://doi.org/10.1161/HYPERTENSIONAHA.120.15026 https://doi.org/10.1093/eurheartj/ehy339 https://doi.org/10.1001/jama.289.16.2073 https://doi.org/10.1002/14651858.CD008170.pub3 https://doi.org/10.5694/mja16.00526 https://doi.org/10.1093/eurheartj/ehw128 https://doi.org/10.1007/s11906-020-01092-8 https://doi.org/10.1097/01.hjh.0000523154.35964.b7 https://doi.org/10.1161/01.CIR.0000091405.00772.6E https://doi.org/10.1016/j.jacc.2008.05.057 https://doi.org/10.1586/erc.09.8 https://doi.org/10.1016/j.cjca.2018.02.022 https://doi.org/10.1161/CIR.0b013e31821daaf6 https://doi.org/10.1038/s41371-020-0349-x https://doi.org/10.1016/j.hfc.2019.06.007 https://doi.org/10.1016/j.jchf.2017.04.012 https://doi.org/10.1161/01.cir.97.1.48 https://doi.org/10.1161/CIR.0000000000000597 https://doi.org/10.1007/s10741-019-09831-z https://doi.org/10.1177/1060028019843644 https://doi.org/10.1515/med-2015-0011 https://doi.org/10.1016/j.jash.2010.02.002 https://doi.org/10.7326/M20-3798 https://doi.org/10.1161/01.HYP.0000107251.49515.c2 https://doi.org/10.1097/HJH.0000000000000065 https://doi.org/10.1161/01.HYP.0000236119.96301.f2 https://doi.org/10.1161/CIR.0000000000000310 https://doi.org/10.1161/HYPERTENSIONAHA.116.08556 https://doi.org/10.1016/s0008-6363(97)00247-2 https://doi.org/10.1093/ehjcvp/pvy032 https://doi.org/10.1016/s0002-9343(03)00158-x https://doi.org/10.36660/abc.20190731 https://doi.org/10.1186/s40885-019-0124-x https://doi.org/10.2174/1381612825666181203092918 https://doi.org/10.1007/s11906-017-0709-2 https://doi.org/10.1001/archinternmed.2010.427 https://doi.org/10.1038/s41371-021-00505-8 https://doi.org/10.1016/j.cjca.2016.02.066 https://doi.org/10.1161/CIRCULATIONAHA.117.028441 https://doi.org/10.1056/NEJM199005313222203 https://doi.org/10.1093/eurheartj/ehz425 https://doi.org/10.11909/j.issn.1671-5411.2019.02.001 https://doi.org/10.1007/s00508-016-0998-5 https://doi.org/10.1038/jhh.2011.104
ContentType	Journal Article
Copyright	2022 The Author(s). Published by S. Karger AG, Basel 2022 The Author(s). Published by S. Karger AG, Basel. 2022 The Author(s). Published by S. Karger AG, Basel . This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel 2022
Copyright_xml	– notice: 2022 The Author(s). Published by S. Karger AG, Basel – notice: 2022 The Author(s). Published by S. Karger AG, Basel. – notice: 2022 The Author(s). Published by S. Karger AG, Basel . This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel 2022
DBID	M-- AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM
DOI	10.1159/000526792
DatabaseName	Karger Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest One Academic Middle East (New) CrossRef MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: M-- name: Karger Open Access url: https://www.karger.com/OpenAccess sourceTypes: Enrichment Source Publisher – sequence: 4 dbid: 7X7 name: ProQuest Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1423-0151
EndPage	462
ExternalDocumentID	PMC9801368 36044874 10_1159_000526792 526792
Genre	Journal Article Review
GroupedDBID	--- 0R~ 0~B 30W 326 36B 3O. 3V. 4.4 53G 5GY 7X7 88E 8FI 8FJ 8UI AAWTL AAYIC ABPAZ ABUWG ACGFS ADBBV AENEX AEYAO AFKRA AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZPMC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CS3 CYUIP DIK DU5 E0A E3Z EBS EMB EMOBN F5P FB. FYUFA GROUPED_DOAJ HMCUK HYE HZ~ IAO IHR KUZGX M-- M1P MK0 O1H O9- OK1 P2P PQQKQ PROAC PSQYO RKO RNS RPM SV3 UJ6 UKHRP AAYXX ABBTS ABWCG ACQXL ADAGL AFJJK AFSIO AHFRZ AIOBO CAG CITATION COF EJD ITC PHGZM PHGZT RIG RXVBD TR2 CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM
ID	FETCH-LOGICAL-c519t-f2a56ad1e609e457df845a18b753db8c89fb8aa58466564a7d7548aa1b9382943
IEDL.DBID	7X7
ISSN	1011-7571 1423-0151
IngestDate	Thu Aug 21 18:40:11 EDT 2025 Thu Jul 10 22:03:51 EDT 2025 Fri Jul 25 23:44:06 EDT 2025 Thu Apr 03 06:57:41 EDT 2025 Sun Jul 06 05:06:58 EDT 2025 Thu Apr 24 22:52:45 EDT 2025 Thu Sep 05 17:57:50 EDT 2024 Thu Aug 29 12:04:39 EDT 2024
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	Heart failure Arterial hypertension Renin-angiotensin-aldosterone system Calcium channel blockers Left ventricular hypertrophy
Language	English
License	This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. https://creativecommons.org/licenses/by-nc/4.0 2022 The Author(s). Published by S. Karger AG, Basel.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c519t-f2a56ad1e609e457df845a18b753db8c89fb8aa58466564a7d7548aa1b9382943
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ORCID	0000-0003-4966-0168 0000-0001-6044-3557
OpenAccessLink	https://karger.com/doi/10.1159/000526792
PMID	36044874
PQID	2900316729
PQPubID	2047984
PageCount	9
ParticipantIDs	proquest_miscellaneous_2709017592 proquest_journals_2900316729 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9801368 karger_primary_526792 crossref_citationtrail_10_1159_000526792 crossref_primary_10_1159_000526792 pubmed_primary_36044874
PublicationCentury	2000
PublicationDate	2022-12-01
PublicationDateYYYYMMDD	2022-12-01
PublicationDate_xml	– month: 12 year: 2022 text: 2022-12-01 day: 01
PublicationDecade	2020
PublicationPlace	Basel, Switzerland
PublicationPlace_xml	– name: Basel, Switzerland – name: Switzerland – name: Basel – name: Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com
PublicationTitle	Medical principles and practice
PublicationTitleAlternate	Med Princ Pract
PublicationYear	2022
Publisher	S. Karger AG
Publisher_xml	– name: S. Karger AG
References	Wolf SJ, Lo B, Shih RD, Smith MD, Fesmire FM; American College of Emergency Physicians Clinical Policies Committee. Clinical policy: critical issues in the evaluation and management of adult patients in the emergency department with asymptomatic elevated blood pressure. Ann Emerg Med. 2013;62(1):59–68. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, . 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334–57. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2011;171(5):384–94. Tsioufis C, Georgiopoulos G, Oikonomou D, Thomopoulos C, Katsiki N, Kasiakogias A, . Hypertension and heart failure with preserved ejection fraction: connecting the dots. Curr Vasc Pharmacol. 2017;16(1):15–22. Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, . The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44):3308–17. Malachias MVB, Barbosa ECD, Martim JFV, Rosito GBA, Toledo JY, PassarelliOJr. 7th Brazilian guideline of arterial hypertension: chapter 14: Hypertensive crisis. Arq Bras Cardiol. 2016;107(3 Suppl 3):79–83. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998;13(3):564–9. Steuber TD, Lee J, Holloway A, Andrus MR. Nondihydropyridine calcium channel blockers for the treatment of proteinuria: a review of the literature. Ann Pharmacother. 2019;53(10):1050–9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, IzzoJLJr, . Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, . 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circ J. 2014;78(11):2779–801. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N Engl J Med. 1990;322(22):1561–6. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, . Clinical practice guidelines for the management of hypertension in the community a statement by the American society of hypertension and the international society of hypertension. J Hypertens. 2014;32(1):3–15. Wachtell K, Kjeldsen S, Devereux R, Okin P. Relationship of incident atrial fibrillation to the electrocardiographic strain pattern in hypertensive patients with electrocardiographic left ventricular hypertrophy. J Hypertens. 2017;35(Suppl 2):e68. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens. 2015;33(7):1321–41. Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, . Effects of Sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. Hypertension. 2017;69(3):411–20. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, . 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, . 2018 Korean society of hypertension guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2018;25:20. Katholi RE, Couri DM. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens. 2011;2011:495349. Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, . Hypertension Canada’s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32(5):569–88. Koracevic G, Stojanovic M, Lovic D, Zdravkovic M, Sakac D. Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk. J Hum Hypertens. 2021;35(7):564–76. Bourdillon MT, Vasan RS. A contemporary approach to hypertensive cardiomyopathy: reversing left ventricular hypertrophy. Curr Hypertens Rep. 2020;22(10):85. Tschanz CMP, Cushman WC, Harrell CTE, Berlowitz DR, Sall JL. Synopsis of the 2020 U.S. department of veterans affairs/US. department of defense clinical practice guideline: the diagnosis and management of hypertension in the primary care setting. Ann Intern Med. 2020;173(11):904–13. Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol. 2008;52(13):1062–72. Shah SN, Munjal YP, Kamath SA, Wander GS, Mehta N, Mukherjee S, . Indian guidelines on hypertension-IV (2019). J Hum Hypertens. 2020;34(11):745–58. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, . ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American college of cardiology foundation task force on clinical expert consensus documents. Circulation. 2011;123(21):2434–506. Soliman EZ, Ambrosius WT, Cushman WC, Zhang ZM, Bates JT, Neyra JA, . Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (systolic blood pressure intervention trial). Circulation. 2017;136(5):440–50. Hua Q, Fan L, Li J, Joint Committee for Guideline Revision. 2019 Chinese guideline for the management of hypertension in the elderly. J Geriatr Cardiol. 2019;16(2):67–99. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, . 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, . The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235–481. Pierdomenico SD, Cuccurullo F. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta‐analysis. Am J Hypertens. 2010;23(8):876–81. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, . Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831–8. Sanchez RA, Ayala M, Baglivo H, Velazquez C, Burlando G, Kohlmann O, . Latin American guidelines on hypertension. Latin American expert group.. Latin American Expert Group. J Hypertens. 2009;27(5):905–22. World Health Organization. Hypertension. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension (accessed January 4, 2022). Chaugai S, Sherpa LY, Sepehry AA, Kerman SRJ, Arima H. Effects of long- and intermediate-acting dihydropyridine calcium channel blockers in hypertension: a systematic review and meta-analysis of 18 prospective, randomized, actively controlled trials. J Cardiovasc Pharmacol Ther. 2018;23(5):433–45. Shimada T, Yoshiyama M, Takeuchi K, Omura T, Takemoto Y, Kim S, . Long-acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats. Cardiovasc Res. 1998;37(3):618–26. Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, . 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Circulation. 2016;133(14):e471–505. Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, . Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020;36(5):596–624. Seedat YK, Rayner BL; Southern African Hypertension Society. South African hypertension guideline 2011. S Afr Med J. 2011;102(1 Pt 2):57–83. Koraćević GP, Dakić SS, Veličković-Radovanović RM, Apostolović SR, Krstić NH, Tasić IS, . Amlodipine as an antiischemic drug is superior to long-acting nitrates. Open Med (Wars). 2015;10(1):50–6. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, . Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97(1):48–54. Almazov VA, Shlyakhto EV, Konrady AO, Macsimova TA, Zaharov DV, Rudomanov OG. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies. Med Sci Monit. 2000;6(2):309–13. Shields DL. Calcium channel blockers as initial therapeutic agents in hypertension: relationship to incident heart failure. Biol Res Nurs. 2014;16(3):266–77. Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, . Predictors ref13 ref57 ref12 ref56 ref15 ref59 ref14 ref58 ref53 ref52 ref11 ref55 ref10 ref54 ref17 ref16 ref19 ref18 ref51 ref50 ref46 ref45 ref48 ref47 ref42 ref41 ref44 ref43 ref49 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref40 ref35 ref34 ref37 ref36 ref31 ref30 ref33 ref32 ref2 ref1 ref39 ref38 ref24 ref23 ref67 ref26 ref25 ref20 ref64 ref63 ref22 ref66 ref21 ref65 ref28 ref27 ref29 ref60 ref62 ref61
References_xml	– reference: Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, . 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. – reference: Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, . Clinical practice guidelines for the management of hypertension in the community a statement by the American society of hypertension and the international society of hypertension. J Hypertens. 2014;32(1):3–15. – reference: Kenya national guidelines for cardiovascular diseases management. 2018. Developed by the Division of Non-Communicable Diseases - Ministry of Health. Available from: www.health.go.ke (accessed February 21, 2022). – reference: Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, . ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American college of cardiology foundation task force on clinical expert consensus documents. Circulation. 2011;123(21):2434–506. – reference: van den Born BJH, Lip GYH, Brguljan-Hitij J, Cremer A, Segura J, Morales E, . ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019;5(1):37–46. – reference: Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54(5):1084–91. – reference: Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, . Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail. 2013;6(2):279–86. – reference: Joint Committee for Guideline Revision. 2018 Chinese guidelines for prevention and treatment of hypertension-A report of the revision committee of Chinese guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16(3):182–241. – reference: Manickavasagam S, Merla R, Koerner MM, Fujise K, Kunapuli S, Rosanio S, . Management of hypertension in chronic heart failure. Expert Rev Cardiovasc Ther. 2009;7(4):423–33. – reference: Steuber TD, Lee J, Holloway A, Andrus MR. Nondihydropyridine calcium channel blockers for the treatment of proteinuria: a review of the literature. Ann Pharmacother. 2019;53(10):1050–9. – reference: Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, . 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104. – reference: Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol. 2008;52(13):1062–72. – reference: Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, . Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97(1):48–54. – reference: Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, . Effects of Sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. Hypertension. 2017;69(3):411–20. – reference: Slivnick J, Lampert BC. Hypertension and heart failure. Heart Fail Clin. 2019;15(4):531–41. – reference: Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, . 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Circulation. 2016;133(14):e471–505. – reference: Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, . Hypertension Canada’s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32(5):569–88. – reference: van den Born BJH, Beutler JJ, Gaillard CAJM, de Gooijer A, van den Meiracker AH, Kroon AA. Dutch guideline for the management of hypertensive crisis: 2010 revision. Neth J Med. 2011;69(5):248–55. – reference: Vilela-Martin JF, Yugar-Toledo JC, Rodrigues Md C, Barroso WKS, Carvalho LCBS, González FJT, . Luso-Brazilian position statement on hypertensive emergencies: 2020. Arq Bras Cardiol. 2020;114(4):736–51. – reference: Seedat YK, Rayner BL; Southern African Hypertension Society. South African hypertension guideline 2011. S Afr Med J. 2011;102(1 Pt 2):57–83. – reference: JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circ J. 2014;78(11):2779–801. – reference: Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens. 2015;33(7):1321–41. – reference: Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41–6. – reference: Almazov VA, Shlyakhto EV, Konrady AO, Macsimova TA, Zaharov DV, Rudomanov OG. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies. Med Sci Monit. 2000;6(2):309–13. – reference: Gabb GM, Mangoni AA, Anderson CS, Cowley D, Dowden JS, Golledge J, . Guideline for the diagnosis and management of hypertension in adults: 2016. Med J Aust. 2016;205(2):85–9. – reference: Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, . Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA. 2003;289(16):2073–82. – reference: Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, IzzoJLJr, . Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52. – reference: Pierdomenico SD, Cuccurullo F. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta‐analysis. Am J Hypertens. 2010;23(8):876–81. – reference: Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, . The valsartan antihypertensive long-term use evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006;48(3):385–91. – reference: Cuspidi C, Sala C, Negri F, Mancia G, Morganti A; Italian Society of Hypertension. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertension. 2012;26(6):343–9. – reference: Bourdillon MT, Vasan RS. A contemporary approach to hypertensive cardiomyopathy: reversing left ventricular hypertrophy. Curr Hypertens Rep. 2020;22(10):85. – reference: Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, . Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34(5):506–25. – reference: Chatterjee S, Bavishi C, Sardar P, Agarwal V, Krishnamoorthy P, Grodzicki T, . Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. Am J Cardiol. 2014;114(7):1049–52. – reference: Shimada T, Yoshiyama M, Takeuchi K, Omura T, Takemoto Y, Kim S, . Long-acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats. Cardiovasc Res. 1998;37(3):618–26. – reference: Hua Q, Fan L, Li J, Joint Committee for Guideline Revision. 2019 Chinese guideline for the management of hypertension in the elderly. J Geriatr Cardiol. 2019;16(2):67–99. – reference: Jekell A, Nilsson PM, Kahan T. Treatment of hypertensive left ventricular hypertrophy. Curr Pharm Des. 2018;24(37):4391–6. – reference: Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012; 33: 1750–7. – reference: Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, . 2018 Korean society of hypertension guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2018;25:20. – reference: Koracevic G, Stojanovic M, Lovic D, Zdravkovic M, Sakac D. Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk. J Hum Hypertens. 2021;35(7):564–76. – reference: SESLHD Hypertension Policy Development Working Party. Management of hypertension in the SESLHD ward settings. South eastern Sydney local health district guideline. SESLHDGL/068. 2018. Available from: https://www.seslhd.health.nsw.gov.au/sites/default/files/documents/SESLHDGL068.pdf (accessed February 21, 2022). – reference: Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, . 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. – reference: Sanchez RA, Ayala M, Baglivo H, Velazquez C, Burlando G, Kohlmann O, . Latin American guidelines on hypertension. Latin American expert group.. Latin American Expert Group. J Hypertens. 2009;27(5):905–22. – reference: Weber T, Lang I, Zweiker R, Horn S, Wenzel RR, Watschinger B, . Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations: a joint scientific statement from the Austrian society of cardiology and the Austrian society of hypertension. Wien KlinWochenschr. 2016;128(13–14):467–79. – reference: Pagliaro BR, Cannata F, Stefanini GG, Bolognese L. Myocardial ischemia and coronary disease in heart failure. Heart Fail Rev. 2020;25(1):53–65. – reference: Tsioufis C, Georgiopoulos G, Oikonomou D, Thomopoulos C, Katsiki N, Kasiakogias A, . Hypertension and heart failure with preserved ejection fraction: connecting the dots. Curr Vasc Pharmacol. 2017;16(1):15–22. – reference: World Health Organization. Hypertension. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension (accessed January 4, 2022). – reference: Katholi RE, Couri DM. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens. 2011;2011:495349. – reference: Shah SN, Munjal YP, Kamath SA, Wander GS, Mehta N, Mukherjee S, . Indian guidelines on hypertension-IV (2019). J Hum Hypertens. 2020;34(11):745–58. – reference: James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311(5):507–20. – reference: Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998;13(3):564–9. – reference: Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC Heart Fail. 2017;5(8):543–51. – reference: Soliman EZ, Ambrosius WT, Cushman WC, Zhang ZM, Bates JT, Neyra JA, . Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (systolic blood pressure intervention trial). Circulation. 2017;136(5):440–50. – reference: Tschanz CMP, Cushman WC, Harrell CTE, Berlowitz DR, Sall JL. Synopsis of the 2020 U.S. department of veterans affairs/US. department of defense clinical practice guideline: the diagnosis and management of hypertension in the primary care setting. Ann Intern Med. 2020;173(11):904–13. – reference: Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, . 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334–57. – reference: Chaugai S, Sherpa LY, Sepehry AA, Kerman SRJ, Arima H. Effects of long- and intermediate-acting dihydropyridine calcium channel blockers in hypertension: a systematic review and meta-analysis of 18 prospective, randomized, actively controlled trials. J Cardiovasc Pharmacol Ther. 2018;23(5):433–45. – reference: Roush GC, Abdelfattah R, Song S, Ernst ME, Sica DA, Kostis JB. Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: a systematic review and meta-analysis. J Clin Hypertens. 2018;20(10):1507–15. – reference: Williams B. Drug treatment of hypertension: implications of ALLHAT. Heart. 2003;89(6):589–90. – reference: Iyer AS, Ahmed MI, Filippatos GS, Ekundayo OJ, Aban IB, Love TE, . Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens. 2010;4(1):22–31. – reference: Cvetkovic E, Koracevic G. A case report of a patient with preserved heart pump function, whose pulmonary edema was precipitated by atrial fibrillation and antiarrhythmics with a negative inotropic effect. Kardiologija. 2000;21:112. – reference: Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N Engl J Med. 1990;322(22):1561–6. – reference: Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, . 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77. – reference: Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, . Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020;36(5):596–624. – reference: Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, . Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67. – reference: Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2011;171(5):384–94. – reference: Koraćević GP, Dakić SS, Veličković-Radovanović RM, Apostolović SR, Krstić NH, Tasić IS, . Amlodipine as an antiischemic drug is superior to long-acting nitrates. Open Med (Wars). 2015;10(1):50–6. – reference: Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, . The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235–481. – reference: Malachias MVB, Barbosa ECD, Martim JFV, Rosito GBA, Toledo JY, PassarelliOJr. 7th Brazilian guideline of arterial hypertension: chapter 14: Hypertensive crisis. Arq Bras Cardiol. 2016;107(3 Suppl 3):79–83. – reference: Shields DL. Calcium channel blockers as initial therapeutic agents in hypertension: relationship to incident heart failure. Biol Res Nurs. 2014;16(3):266–77. – reference: Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, . The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44):3308–17. – reference: Whelton PK, Carey RM, Aronow WS, Casey DEJr, CollinsKJ, Dennison Himmelfarb C, . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2018;138(17):e426–83. – reference: Tam MC, Lee R, Cascino TM, Konerman MC, Hummel SL. Current perspectives on systemic hypertension in heart failure with preserved ejection fraction. Curr Hypertens Rep. 2017;19(2):12. – reference: Wolf SJ, Lo B, Shih RD, Smith MD, Fesmire FM; American College of Emergency Physicians Clinical Policies Committee. Clinical policy: critical issues in the evaluation and management of adult patients in the emergency department with asymptomatic elevated blood pressure. Ann Emerg Med. 2013;62(1):59–68. – reference: Academy of Medicine of Malaysia. The clinical practise guidelines (CPGs); management of hypertension (5th edition) 2018. 2018. Available from: http://www.acadmed.org.my/index.cfm?menuid=67 (accessed February 21, 2022). – reference: Wachtell K, Kjeldsen S, Devereux R, Okin P. Relationship of incident atrial fibrillation to the electrocardiographic strain pattern in hypertensive patients with electrocardiographic left ventricular hypertrophy. J Hypertens. 2017;35(Suppl 2):e68. – reference: Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, . Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831–8. – reference: Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q, . First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2018;11:CD008170. – ident: ref32 doi: https://doi.org/10.1016/S0140-6736(15)01225-8 – ident: ref60 doi: https://doi.org/10.1177/1099800413494760 – ident: ref20 doi: https://doi.org/10.1016/j.amjcard.2014.07.015 – ident: ref56 doi: https://doi.org/10.1016/j.cjca.2020.02.086 – ident: ref39 doi: https://doi.org/10.1161/HYPERTENSIONAHA.109.136655 – ident: ref37 doi: https://doi.org/10.1038/ajh.2010.80 – ident: ref52 doi: https://doi.org/10.5935/abc.20160164 – ident: ref48 doi: https://doi.org/10.1093/ndt/13.3.564 – ident: ref29 doi: https://doi.org/10.1253/circj.cj-66-0098 – ident: ref22 doi: https://doi.org/10.1001/jama.2013.284427 – ident: ref34 doi: https://doi.org/10.1097/HJH.0000000000000614 – ident: ref45 doi: https://doi.org/10.1093/eurheartj/ehx525 – ident: ref11 doi: https://doi.org/10.1161/CIRCHEARTFAILURE.112.972828 – ident: ref33 doi: https://doi.org/10.1177/1074248418771341 – ident: ref21 doi: https://doi.org/10.1016/j.annemergmed.2013.05.012 – ident: ref42 doi: https://doi.org/10.1111/jch.13386 – ident: ref50 doi: https://doi.org/10.1097/HJH.0b013e32832aa6d2 – ident: ref67 doi: https://doi.org/10.1136/heart.89.6.589 – ident: ref2 doi: https://doi.org/10.1038/s41440-019-0284-9 – ident: ref4 doi: https://doi.org/10.1093/eurheartj/eht151 – ident: ref19 doi: https://doi.org/10.2174/1570161115666170414120532 – ident: ref24 doi: https://doi.org/10.11909/j.issn.1671-5411.2019.03.014 – ident: ref14 doi: https://doi.org/10.4061/2011/495349 – ident: ref26 doi: https://doi.org/10.1161/HYPERTENSIONAHA.120.15026 – ident: ref1 doi: https://doi.org/10.1093/eurheartj/ehy339 – ident: ref65 doi: https://doi.org/10.1001/jama.289.16.2073 – ident: ref58 doi: https://doi.org/10.1002/14651858.CD008170.pub3 – ident: ref51 doi: https://doi.org/10.5694/mja16.00526 – ident: ref18 doi: https://doi.org/10.1093/eurheartj/ehw128 – ident: ref13 doi: https://doi.org/10.1007/s11906-020-01092-8 – ident: ref17 doi: https://doi.org/10.1097/01.hjh.0000523154.35964.b7 – ident: ref44 doi: https://doi.org/10.1161/01.CIR.0000091405.00772.6E – ident: ref64 doi: https://doi.org/10.1016/j.jacc.2008.05.057 – ident: ref15 doi: https://doi.org/10.1586/erc.09.8 – ident: ref25 doi: https://doi.org/10.1016/j.cjca.2018.02.022 – ident: ref10 doi: https://doi.org/10.1161/CIR.0b013e31821daaf6 – ident: ref3 doi: https://doi.org/10.1038/s41371-020-0349-x – ident: ref6 doi: https://doi.org/10.1016/j.hfc.2019.06.007 – ident: ref61 doi: https://doi.org/10.1016/j.jchf.2017.04.012 – ident: ref38 doi: https://doi.org/10.1161/01.cir.97.1.48 – ident: ref23 doi: https://doi.org/10.1161/CIR.0000000000000597 – ident: ref8 doi: https://doi.org/10.1007/s10741-019-09831-z – ident: ref31 doi: https://doi.org/10.1177/1060028019843644 – ident: ref28 doi: https://doi.org/10.1515/med-2015-0011 – ident: ref62 doi: https://doi.org/10.1016/j.jash.2010.02.002 – ident: ref57 doi: https://doi.org/10.7326/M20-3798 – ident: ref5 doi: https://doi.org/10.1161/01.HYP.0000107251.49515.c2 – ident: ref35 doi: https://doi.org/10.1097/HJH.0000000000000065 – ident: ref66 doi: https://doi.org/10.1161/01.HYP.0000236119.96301.f2 – ident: ref30 doi: https://doi.org/10.1161/CIR.0000000000000310 – ident: ref46 doi: https://doi.org/10.1161/HYPERTENSIONAHA.116.08556 – ident: ref49 doi: https://doi.org/10.1016/s0008-6363(97)00247-2 – ident: ref53 doi: https://doi.org/10.1093/ehjcvp/pvy032 – ident: ref40 doi: https://doi.org/10.1016/s0002-9343(03)00158-x – ident: ref55 doi: https://doi.org/10.36660/abc.20190731 – ident: ref36 doi: https://doi.org/10.1186/s40885-019-0124-x – ident: ref41 doi: https://doi.org/10.2174/1381612825666181203092918 – ident: ref9 doi: https://doi.org/10.1007/s11906-017-0709-2 – ident: ref59 doi: https://doi.org/10.1001/archinternmed.2010.427 – ident: ref43 doi: https://doi.org/10.1038/s41371-021-00505-8 – ident: ref47 doi: https://doi.org/10.1016/j.cjca.2016.02.066 – ident: ref63 doi: https://doi.org/10.1161/CIRCULATIONAHA.117.028441 – ident: ref16 doi: https://doi.org/10.1056/NEJM199005313222203 – ident: ref27 doi: https://doi.org/10.1093/eurheartj/ehz425 – ident: ref54 doi: https://doi.org/10.11909/j.issn.1671-5411.2019.02.001 – ident: ref7 doi: https://doi.org/10.1007/s00508-016-0998-5 – ident: ref12 doi: https://doi.org/10.1038/jhh.2011.104
SSID	ssj0008330
Score	2.324003
SecondaryResourceType	review_article
Snippet	Arterial hypertension (HTN) is important due to its high prevalence, morbidity, and mortality rates. Calcium channel blockers (CCBs) are the first-line...
SourceID	pubmedcentral proquest pubmed crossref karger
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	454
SubjectTerms	Antihypertensive Agents - therapeutic use Antihypertensives Blood pressure Calcium Channel Blockers - therapeutic use Cardiovascular disease Diuretics Drugs Ejection fraction Heart attacks Heart failure Heart Failure - complications Heart Failure - drug therapy Heart Failure - prevention & control Humans Hypertension Hypertension - complications Hypertension - drug therapy Hypertension - epidemiology Hypertrophy, Left Ventricular - drug therapy Hypertrophy, Left Ventricular - prevention & control Mortality Original Paper Prevention Risk factors
SummonAdditionalLinks	– databaseName: Karger Open Access dbid: M-- link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Lb9QwELZQQVUviEeBhYIGxIGLRR52bHMrhdUKsVUPLeotshNbjbok1Tb7o_ovO46diF2Va2ZiJ5oZzzfJ-DMhn33FlTiXU-uEoUywimrJOcUYxyIoEw7v890Wp8Xigv265Jfxe4ffC3Pt-58HatSJWwAT7tfASyIULraPsY7KffPektJpzZV5HngH0pQKLtLIIbR16wHZz4sEyxHBtpLQkzDnQxBzt1Pyn9Qzf0aeRswIx8HIz8kj274g-8v4V_wluTuGHw2GP2YWXCq_wYleVc3mL_idA61dwXdMWNcI83AEC4GuGNc4QLgKCP_gfOw1h87BAuvSdexqh9_W9fDHP1QztKtG6bpD24DZ9HDa9aBvd8YcWaG6dhgQQ6mHuW58__shuZj_PD9Z0HgEA60Q2vXUZZoXuk5tkSjLuKidZFyn0mCVUxtZSeWM1NqjGASGTItaYAmkdWpULjPF8ldkr-1a-4aA4tZoa51RHD2CGS3r1KWVPyu4zhNbz8iX0SZlFfnJ_TEZq3KoU7gqJ0vOyKdJ9SaQcjykdBgMO6mM1492ri_PzoKovKkdikc3KGM435aZ_96bFliIzMjHSYyB6P-u6NZ2G9QRCWIrwf0Mr4PXTDOMfjcjYsufJgVP8r0taZurgexbSc-qJ9_-523ekYPMb8gYGmyOyF6_3tj3CJN682GIkHsAtw4D priority: 102 providerName: Karger AG
Title	A Discrepancy: Calcium Channel Blockers Are Effective for the Treatment of Hypertensive Left Ventricular Hypertrophy but Not as Effective for Prevention of Heart Failure
URI	https://karger.com/doi/10.1159/000526792 https://www.ncbi.nlm.nih.gov/pubmed/36044874 https://www.proquest.com/docview/2900316729 https://www.proquest.com/docview/2709017592 https://pubmed.ncbi.nlm.nih.gov/PMC9801368
Volume	31
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgQ4gXxGVAd6kM4oEXa7k5dniZtrGqQrSq0Ib6FtmJrUUrSdemP4p_yTmJE9Zq4iUP8YkT6Vz8HfvkO4R8xozLszZkxgrNIhFlTEnOGfg4JEGBsPAcVltM4_FN9H3O527Dbe3KKruY2ATqvMpwj_w0wC03PwYseLa8Z9g1Ck9XXQuNp2QfqcvQqsW8T7gAXYQtG4HvM8GF75iFYAU_bYlORBJsrUfP7rD8evUY2twtmnywCo1ekZcOPtLzVt-vyRNTviHPJ-6A_C35c06_FRAJYJGBqPmVXqpFVmx-U_yJoDQLegFr1x0gPpjB0Ja5GMIdBeRKAQnS667snFaWjiFFXbkCd_rD2Jr-wo8qmspVN7qqQE1Ub2o6rWqq1jtzdgRRVdlMCF5V05EqsBT-gNyMrq4vx8x1Y2AZoLya2UDxWOW-ib3ERFzkVkZc-VJDwpNrmcnEaqkUAhrAiJESuYBsSClfJ6EMkih8R_bKqjQfCE240coYqxMOxhFpJXPf-hm2Dc5Dz-QD8qXTSZo5qnLsmLFIm5SFJ2mvvgH51IsuW36Ox4QOWsX2It394537k9msHUqXuYXhzgxS59nr9J8dDsjHfhh8Eg9aVGmqDcgID2CW4PiG963V9G8IYw8yYhENiNiyp14A-b63R8rituH9TiQS7MnD_3_WEXkR4C8aTcnNMdmrVxtzAsCp1sPGO4Zk_-JqOvs5bLYf4Dph7C8VnRzE
linkProvider	ProQuest
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGQMAL4mOwwgCDQOIlWr4cO0gIjY2qY221hw71LbNjW0TrktKmQvxJvPA3cpcvaDXxtlffxYl057vfxeefCXmDFZdrbeAYy5UT8jB1pGDMgTUORZDPLTyH3RbjaHAWfpmy6Rb53Z6FwbbKNiZWgVoXKf4j3_fxl5sXARb8OP_u4K1RuLvaXqFRu8WJ-fkDSrblh-MjsO9b3-9_nhwOnOZWAScFtFI61pcsktozkRubkHFtRcikJxQAd61EKmKrhJSYmAHrhJJrDqheSk_FgfDjMIB5b5CbkHhdLPb4tCvwAM0ENfuB5zmcca9hMgLEsF8Tq_DYX8t_ty6w3XtxFbrdbNL8J-v175N7DVylB7V_PSBbJn9Ibo-aDflH5NcBPcog8kBSgyj9nh7KWZqtLikeWsjNjH6CXHkBCBNmMLRmSobwSgEpU0CedNK2udPC0gGUxIumoZ4OjS3pV_yorOqUbaSLAtyCqlVJx0VJ5XJjzpaQqsirCcFcJe3LDFvvd8jZtdjpMdnOi9zsEhozo6QxVsUMnDFUUmjPeileU6wD1-geedfaJEkbanS8oWOWVCUSi5POfD3yulOd13wgVynt1IbtVNrxvY3x0elpLUrm2oK4dYOkiSTL5K_f98irTgwxADd2ZG6KFehwF2AdZ_iGJ7XXdG8IIhcqcB72CF_zp04B-cXXJXn2reIZjwUS-omn__-sl-TOYDIaJsPj8ckzctfH4yFVu88e2S4XK_McQFupXlQrhZLz616afwB56FWS
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGhyZeEB8DOgYYBBIvUfPl2EFCaFtXdWyrKrShvWV2YotqXVLaVIg_iX-Bv467xAm0mnjbq-_iRLqv38XnO0LeYsblGhM42nDlhDxMHSkYc8DGIQnyuYHnsNpiFA3Pw88X7GKD_G7uwmBZZeMTK0edFSn-I-_5-MvNiwAL9owtixj3B59m3x2cIIUnrc04jVpFjvXPH5C-LT4e9UHW73x_cHh2MHTshAEnBeRSOsaXLJKZpyM31iHjmREhk55QAOIzJVIRGyWkxCANuCeUPOOA8KX0VBwIPw4D2PcO2eSYFXXI5v7haPyljQMiCOpeCJ7ncMY929cI8EOvbrPCY38lGt69wuLv-U1Yd71k858YOHhA7lvwSvdqbXtINnT-iGyd2uP5x-TXHu1PwA9BiAOf_YEeyGk6WV5TvMKQ6yndh8h5BXgTdtC07psMzpYCbqaAQ-lZU_ROC0OHkCDPbXk9PdGmpF_xoyZV3aylzgtQEqqWJR0VJZWLtT2b9lRFXm0IAivpQE6wEH-bnN-KpJ6QTl7k-hmhMdNKam1UzEA1QyVF5hkvxaHFWeDqrEveNzJJUtsoHed1TJMqYWJx0oqvS960rLO6O8hNTNu1YFuWZn13bf10PK5JySwzQG7UILF-ZZH8tYIued2SwSPgMY_MdbEEHu4CyOMM3_C01pr2DUHkQj7Owy7hK_rUMmC38VVKPvlWdR2PBbb3Ezv__6xXZAvMMjk5Gh0_J_d8vCtS1f7skk45X-oXgOBK9dKaCiWXt22dfwAmK1st
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Discrepancy%3A+Calcium+Channel+Blockers+Are+Effective+for+the+Treatment+of+Hypertensive+Left+Ventricular+Hypertrophy+but+Not+as+Effective+for+Prevention+of+Heart+Failure&rft.jtitle=Medical+principles+and+practice&rft.au=Koracevic%2C+Goran&rft.au=Perisic%2C+Zoran&rft.au=Stanojkovic%2C+Maja&rft.au=Stojanovic%2C+Milovan&rft.date=2022-12-01&rft.pub=S.+Karger+AG&rft.issn=1011-7571&rft.eissn=1423-0151&rft.volume=31&rft.issue=5&rft.spage=454&rft.epage=462&rft_id=info:doi/10.1159%2F000526792&rft.externalDBID=HAS_PDF_LINK
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-7571&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-7571&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-7571&client=summon